<DOC>
	<DOCNO>NCT01523340</DOCNO>
	<brief_summary>1 . Trial design : Prospective observational study 2 . Target population : 200 NSCLC patient histologically cytologically confirm stage IV recurrent NSCLC progressive disease 1st line chemotherapy consent study participation meet study selection criterion 3 . Primary objective : To investigate C-met expression/amplification EGFR gene mutation NSCLC patient treat Erlotinib - C-met expression IHC C-met amplification SISH EGFR mutation real time PCR 4 . We also assess correlation EGFR mutation c-MET clinical outcome ( Overall Response Rate , Progression Free survival ) 5 . Duration Trial Recruitment : 2 year</brief_summary>
	<brief_title>A Prospective Observational Study Evaluating c-MET Expression EGFR Gene Mutation Correlation With Erlotinib Response</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Informed consent 19~80 year old male female Histologically proven advance metastatic NSCLC Failed 1st line chemotherapy Tumor tissue genetic analysis Evaluable target lesion RECIST v1.1 ECOG performance 0 3 Expected survival 12 week Previous treatment EGFRtyrosine kinase inhibitor Severe hypersensitivity erlotinib Residual toxicity ( grade 2 ) previous chemotherapy Total bilirubin 1.5x upper normal limit Liver function test 2.5x upper normal limit</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>